

# State of Illinois Drugs and Therapeutics Advisory Board

## Minutes for October 21, 2021

### Minutes

- I. Dr. Florence opened the meeting at 8:34am
- II. Roll Call was taken. Dr. Berkowitz was excused from attendance.
- III. No conflicts of Interest
- IV. July meeting minutes are unanimously approved
- V. Public Testimony

Speaker	Product	Organization
Brooke Wilkins, PharmD	Kesimpta	Novartis
Karen Malamut, DO	Verquvo (destified during review)	Merck
Vignesh Shettar, MD	Rybelsus (destified during review)	Macneal Endocrinology
Opeoluwa Fagbemi, Senior Regional Medical Manager	Qelbree (destified during review)	Supernus
Rick Szymialis, Field HEOR Director	Zeposia	Bristol Myers Squibb
Adil Javed, MD, Phd.	Ocrevus	Genentech

- VI. Rybelsus Clarification-The Department expressed concern that this drug was recommended as preferred at the July meeting based solely on convenience as the only oral product. The Department was concerned that the drug lacks the cardio-protective qualities that the 2 agents already preferred possess. Dr. Rodriguez outlined the Department's clinical concerns. No Cardio protective indications will be expected before 2024 when trials are finished. Dr. Vignesh Shettar testified to his favorable use and opinion of the product. Board recommendation is based more on adherence to treatment then on cardiac protection. After much discussion the recommendation was made to make Rybelsus available with no prior approval.
- VII. PDL Appeals-None for this meeting.
- VIII. New Drug Appeals-None for this meeting.
- IX. Rodriguez, PharmD. presented each class monograph.
  - a. Growth Hormones-Dr. Rodriguez presented a clinical overview of the class noting that differentiation in efficacy is hard to measure due to the lack of comparative studies. After discussion, the recommendation was made to leave Genotropin as the preferred product and the class as it is currently.
  - b. Multiple Sclerosis-Oral Agents-Dr. Rodriguez presented the clinical overview of the class. There are several new products and generics in the class. The studies show that dimethylfumerate may be most effective in the fumarates with the least side effects. Fingolamod is also very effective with low side effect profiles and is indicated for pediatric patients. Guidelines have 2 options: 1. Start with lower efficacy and go up. 2. To start high and add others as needed. Right now the PDL requires a step through Interferon or Glatiramer is clinically appropriate for the patient. The guidelines do not pose a strong recommendation for one specific agent. Board recommendation is that these remain on preferred with PA but not necessarily require a step through an injectable in the physician feels and oral is more appropriate for the patient.

- c. Multiple Sclerosis-Injectable Agents-Dr. Rodriguez presented an overview of this class. Again, we have several new agents in this group for Relapsing Remitting MS. Only Ocrevus is indicated for Primary Progressive. The monoclonal antibodies have higher infection risk. Cyndi VanSteenburg asked for the Board to consider recommending the 40mg dose for the Copaxone or it's generic. Also, Plegridy or Avonex over the Rebif and Betaseron. Garry Moreland spoke to the fact that some patients experience more side effects with the longer acting products. Recommendation was to make glatiramer 40mg preferred as well as the 20mg dose. A second recommendation was to make Plegridy or Avonex preferred on the basis of less frequent dosing without PA.
- X. New Drug Initial Review
  - a. Qelbree- Opeoluwa Fagbemi presented for the manufacturer. Dr. Rodriguez presented a review of the product. The Board voted to leave this as non-preferred.
  - b. Verquvo-Dr. Rodriguez presented a review of the product. Karen Malamut, DO presented the drug on behalf of the manufacturer. Board discussion was around availability and hospital readmission. This is to be used as adjunct therapy. Roll Call vote was asked for by Dr. Goyal.
    - Florence-yay
    - Patel-Nay
    - Goyal-Abstain
    - Albers-yay
    - Allbright-Nay
    - Moreland-Yay
    - Rodriguez-Yay
    - Shaw-Yay
    - Berkowitz-Absent
    - To be available with no PA.
- XI. Future Agenda Preview-Sheri Dolan shared that the dates for the 2022 meetings will be:
  - January 13, 2022
  - April 14, 2022
  - July 14, 2022
  - October 13, 2022
- XII. Provider Requested Reviews- None for this meeting
- XIII. Department Update-Jose Jimenez thanked everyone for their work on this board. He also asked for any recommendations for resumes for the DUR Board. COVID-19 and the department information share was also addressed.
- XIV. Adjournment-Dr. Florence adjured the meeting at 10:47am.

## Attendees

The names of the Board members and speakers are bolded.

### Panelist List

1. Alyssa Stephenson
2. Sheri Dolan
3. **Cynthia VanSteenburg**
4. Jose Jimenez
5. **Nicole Florence**
6. Donna Clay
7. **Arvind Goyal**
8. **Garry Moreland**
9. **Ryan Rodriguez**
10. **Maurice Shaw**
11. **Janet Albers**
12. **Deborah Albright**
13. Jennifer DeWitt
14. Heather Freeman
15. **Pamela Vergara-Rodriquez**
16. Mary Moody
17. **Mahesh Patel**

### Attendee List

1. Akesha Coleman
2. **Adil Javed**
3. Bradley Kalkwarf
4. **Brooke Wilkins**
5. Call in User 10
6. Call in User 11
7. Call in User 12
8. Call in User 3
9. Call in User 6
10. Call in User 9
11. Chris Stanfield
12. Colleen Dodson
13. Dan Coleman
14. Dan Murphy
15. Doug Johnson
16. Elizabeth Plouff
17. Emma Selm-Keck

18. Garth Wright
19. George Vass
20. Honey Joseph
21. Jason Misna
22. Jenny Carrell
23. Jerry Lubben
24. John Bullard
25. Joseph Dang
- 26. Karen Malamut**
27. Ken Ring
28. Ken Ryan
29. Kendra Kormos
30. Laura Jordan
31. Lisa Nee
32. Lisa Tracz
33. Mark Friederich
34. Martin Matthews
35. Mary Kaneaster
36. Matthew Bradley
37. Michael Chen
38. Michael Hawks
39. Michele Hansen
40. Mike Lloyd
41. Mona Martin
42. Mike Maginn
43. Neelesh Nadkarni
44. Nikki Asse
- 45. Opeoluwa Fagbemi**
46. Petrykiw Petrykiw
47. Ravish Patel
48. Razen Hendi
- 49. Rick Szymialis**
50. Robert Kilo
51. Robert Wright
52. Sakib Hassan
53. Samaneh Ghassemi
54. Sara Gao
55. Sheron Robinson
56. Stormy Cameron
57. Tammy Bima
58. Thao Tran
59. Thomas Erickson
60. Thomas Vayalil
61. Tiawana Parker

**62. Vignesh Shettar**

63. Yvonne Collins